Lifitegrast, Bezlotoxumab, and Sugammadex sodium

J Am Pharm Assoc (2003). 2017 Mar-Apr;57(2):284-287. doi: 10.1016/j.japh.2017.02.004.
No abstract available

Publication types

  • Letter
  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Neutralizing / therapeutic use*
  • Broadly Neutralizing Antibodies
  • Clostridium Infections / drug therapy
  • Dry Eye Syndromes / drug therapy
  • Humans
  • Neuromuscular Agents / therapeutic use*
  • Ophthalmic Solutions / therapeutic use*
  • Phenylalanine / analogs & derivatives*
  • Phenylalanine / therapeutic use
  • Practice Guidelines as Topic
  • Sugammadex / therapeutic use*
  • Sulfones / therapeutic use*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Broadly Neutralizing Antibodies
  • Neuromuscular Agents
  • Ophthalmic Solutions
  • Sulfones
  • lifitegrast
  • Sugammadex
  • Phenylalanine
  • bezlotoxumab